Found
Found58
About
Pricing
View pricing page ↗
What does Found do?
Found is a weight care platform offering personalized weight loss medication, including brand-name GLP-1s like Ozempic®, Mounjaro®, and Zepbound®, as well as compounded tirzepatide and semaglutide. The company helps individuals achieve weight loss and improve related health conditions such as sleep apnea, diabetes, and high blood pressure, with options for insurance coverage and microdosing programs.
What is Found's Effective Domain Rating?
StartupHub's Effective Domain Rating for Found is 43 out of 100, measuring real cross-surface visibility in search engines and AI answers rather than claimed link authority. That is overrated against its Ahrefs Domain Rating of 74, meaning its claimed authority outpaces how often it actually surfaces in search and AI results.
Is Found trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Found is 52 out of 100, based on site security posture and privacy practices.
What is Found's revenue?
StartupHub estimates Found's annual revenue at $20.9M (range $11.2M to $27.4M, 65% confidence), based on comparable companies in the sector.
What is Found's valuation?
StartupHub estimates Found's effective valuation at $465.2M (range $325.6M to $604.7M, 32% confidence), based on comparable companies in the sector.
How much funding has Found raised?
Found has raised a total of $206M in funding. The most recent round on record is Series B.
Where is Found headquartered?
Found is headquartered in San Francisco, United States.
When was Found founded?
Found was founded in 2019.
What industry does Found operate in?
Found operates in HealthTech, Telemedicine, Weight Management, Digital Health, Personalized Medicine, Behavioral Health.
How many employees does Found have?
Found has approximately 147 people on record.
Found and WeightWatchers both offer weight management programs that include medication and behavioral support.
Eli Lilly and Company would gain a direct-to-consumer telehealth platform for weight care, expanding its reach beyond pharmaceutical development and into integrated patient support.
Novo Nordisk could acquire Found to integrate a telehealth weight management platform with its leading GLP-1 medications, offering a comprehensive solution to patients.
AstraZeneca could acquire Found to enhance its presence in the obesity and weight management market by adding a digital health platform that combines medication and behavioral support.
Precedent: AstraZeneca acquired SixPeaks Bio in 2025, an obesity drug startup.
Teladoc Health could integrate Found's specialized weight care platform into its broader virtual care offerings, expanding its services in a high-demand area.
Precedent: Teladoc Health acquired InTouch Health in 2020, a telehealth technology provider for hospitals.
Strategic fit inferred by StartupHub from each buyer's own acquisition history. No deal, approach or discussion is implied.
AI-powered platform for healthcare providers to manage patient WhatsApp messages efficiently.
AI-powered platform for personalized weight management and health coaching.
Clinical Trial Discovery by ENSCORE.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Medbytes provides doctors with a personalized platform for high-impact medical research and news in their specialty.
SYLARIS™ offers premium wearable wellness patches and clinical-grade skincare designed for effortless, intentional, and beautifully designed self-care rituals.
Provider-supervised peptide therapy, NAD+ support, and cognitive enhancement for cellular renewal, recovery, and healthy aging.
Purpose-built WordPress plugins for healthcare and the agencies that serve them.
An entrant is a company tagged HealthTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 6 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.